Cancer Risk and Thiazolidinediones in Diabetic Patients
Author Information
Author(s): Maria E Ramos-Nino, Charles D MacLean, Benjamin Littenberg
Primary Institution: University of Vermont
Hypothesis
Is there an association between thiazolidinedione (TZD) use and cancer prevalence in patients with diabetes?
Conclusion
The study suggests an association between TZD use and cancer in patients with diabetes, particularly with rosiglitazone and among women.
Supporting Evidence
- The study found that 12.6% of participants had a history of cancer.
- Use of TZDs was associated with a higher cancer prevalence, especially in women.
- Rosiglitazone users had a significantly higher odds ratio for cancer compared to non-users.
Takeaway
This study found that people with diabetes who take certain diabetes medications called TZDs might have a higher chance of getting cancer.
Methodology
A cross-sectional analysis was performed on 1003 subjects who self-reported their cancer history and medication use.
Potential Biases
Potential confounding factors were not fully controlled, and the study design is observational.
Limitations
The study lacked confirmation of cancer diagnoses and specific details about cancer types or stages.
Participant Demographics
The study included adults with diabetes, predominantly white, with a mean age of 64.8 years.
Statistical Information
P-Value
0.04
Confidence Interval
1.03–2.44
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website